- Services
- ABL1 Kinase Domain Mutation Analysis
- Chimerism Assessment by Polymorphic Microsatellite Markers
- Detection of BCR ABL Major Fusion Transcripts
- Detection of BCR ABL Minor Fusion Transcripts
- EndLeukemia RNA Translocation Assay Analysis
- FIP1L1-PDGFRA Fusion Transcript Detection
- FLT3 Mutational Analysis
- hMLH1 Methylation Status
- Immunoglobulin Heavy Chain Gene Rearrangement
- Inv(16)(p13.1q22);CBFB-MYH11 Fusion Transcript Detection
- JAK2 p.V617F Mutational Analysis
- EndLeukemia Assay
- MD EndLymphoma Mutation Analysis
- MD FLT3-ITD Follow up Mutation MRD Analysis
- MD Focused Pharamacogenomics Genotyping Assay
- MD HPV Liquid Biopsy
- MD NPM1 MRD Mutation Analysis
- MDA Mutation Analysis Precision Panel Liquid Biopsy
- MGMT Methylation Status
- Microsatellite Instability Analysis (Tumors)
- PML-RARA/t(15;17) Fusion Transcript Detection
- RUNX1-RUNX1T1/t(8;21)(q22;q22) Fusion Transcript Detection
- Somatic Hypermutation Analysis, IGH
- T cell Receptor Beta Gene Rearrangement
- T cell Receptor Gamma Gene Rearrangement
- TGFB1 Polymorphism Real-Time PCR Genotyping
CBFB-MYH11 Fusion Transcript Detection
Detecting the CBFB-MYH11 Fusion Transcript associated with the inv(16)(p13.1q22) via quantitative RNA-PCR
Detecting the CBFB-MYH11 Fusion Transcript associated with the inv(16)(p13.1q22) via quantitative RNA-PCR
Indication
For determining the presence or absence of the CBFB-MYH11 fusion transcript associated with the inv(16)(p13.1q22) chromosomal abnormality seen in 5 to 8% of acute myeloid leukemia (AML) cases as defined by the 2008 WHO classification and AML-M4Eo cases per the prior FAB classification. This quantitative test can be used for establishing the diagnosis of AML with recurrent genetic abnormalities per 2008 WHO classification and for monitoring levels of minimal residual disease following therapy.
Methodology
RNA is analyzed for CBFB-MYH11 fusion by reverse transcription followed by quantitative real-time PCR using the TaqMan method.
Test Parameters
This assay will detect the Type A CBFB-MYH11 fusion transcripts. Values are expressed as a percentage of CBFB-MYH11 to normalizing ABL transcripts. The sensitivity of detection is approximately 1 in 100,000.
Turnaround Time
Five to 10 working days
Sample Requirements
CPT Codes
81401
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.